| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.8M | — | +0.8% |
| Cost of Revenue | $1.3M | — | +5.3% |
| R&D Expense | $66.2M | — | +54.5% |
| SG&A Expense | $20.0M | — | +22.4% |
| Operating Income | -$93.3M | — | -46.0% |
| Net Income | -$88.6M | — | -38.3% |
| EPS (Basic) | -$0.40 | — | -5.3% |
| EPS (Diluted) | -$0.40 | — | -5.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $666.7M | -9.5% | +90.7% |
| Accounts Receivable | $24.3M | -20.6% | -3.5% |
| Inventory | $3.7M | +4.9% | +14.3% |
| Current Assets | $706.0M | -9.7% | +82.1% |
| Total Assets | $732.5M | -9.3% | +80.5% |
| Current Liabilities | $47.7M | -6.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$66.0M | — | -47.7% |
| Capital Expenditures | $4.7M | — | +141.2% |
| Investing Cash Flow | -$4.7M | — | -141.2% |
| Financing Cash Flow | $294K | — | -93.0% |
| Free Cash Flow | -$70.7M | — | -51.6% |
| +25.7% |
| Total Liabilities | $151.0M | -1.8% | +7.8% |
| Stockholders' Equity | $581.6M | -11.1% | +118.7% |